

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

AMERIGEN PHARMACEUTICALS LIMITED and
ARGENTUM PHARMACEUTICALS LLC,
Petitioner,
v.

JANSSEN ONCOLOGY, INC.,
Patent Owner

Case IPR2016-00286
Patent 8,822,438 B2¹

**ARGENTUM'S STIPULATED WITHDRAWAL OF
MAHALINGAM DECLARATION**

¹ Case IPR2016-01317 has been joined with this proceeding.

As ordered by the Board in IPR2016-01317 (Paper 30), Argentum Pharmaceuticals LLC hereby files this stipulation that it withdraws the declaration of Dr. Devalingam Mahalingam (Ex. 1073) and relies instead on the declaration and testimony of Amerigen's expert, Dr. Scott Serels.

Respectfully submitted,

Date: September 30, 2016

/Teresa Stanek Rea/

Teresa Stanek Rea
Reg. No. 30,427
CROWELL & MORING LLP
Intellectual Property Group
P.O. Box 14300
Washington, DC 20044-4300

Counsel for Argentum

**Filed on behalf of Argentum
Pharmaceuticals by William D.
Hare, lead counsel for Petitioner.**

CERTIFICATION OF SERVICE

The undersigned hereby certifies that the foregoing document entitled ARGENTUM'S STIPULATED WITHDRAWAL OF MAHALINGAM DECLARATION was served electronically via email on September 30, 2016 to Patent Owner's counsel of record and counsel of record for Petitioners Argentum, at the following:

Patent Owner

JANS-ZYTIGA@akingump.com
ZytigaIPRTeam@sidey.com

Petitioner Argentum

trea@crowell.com
slentz@crowell.com

Respectfully submitted,

/william hare/
William D. Hare
Reg. No. 44,739
McNeely, Hare, & War LLP
12 Roszel Road, Suite C104
Princeton, NJ 08540